Bruce Japsen
Here are some examples cited of what the Viohl study said some state Medicaid programs are doing to curb Sovaldi costs....
several states, including Arizona, have implemented a “once in a lifetime” rule that allows Medicaid patients one opportunity at treatment with Sovaldi
Alaska requires the patient candidate for Sovaldi to abstain from using drugs and alcohol for at least three months. Then, the patient has to submit to a urine test to verify being drug free
West Virginia only allows a board certified gastroenterologist, hepatologist or infectious disease specialist to prescribe Sovaldi
Several states won’t pay for any lost or stolen Sovaldi
Illinois, which requires patients to meet more than two dozen criteria before they get Sovaldi, will only dispense the drug for two weeks at a time for a total of 12 weeks.
all these problems have arisen due to Gilead's exec's unbounded greed overpricing Harvoni out of reach to dying patents.. So it will be no surprise when I read from my local newspaper that dying patients walk into Gilead's various offices and give back some of the death and pain the so deserving greedy bastards children deserve so badly.
ReplyDeleteThe Indian Patent Controller has today rejected one of Gilead’s key patent applications which covered the drug sofosbuvir, used to treat hepatitis C (HCV). The oral drug, which first received regulatory approval in the US in November 2013, and has been priced by Gilead at US$84,000 for a treatment course, or $1,000 per pill in the US, has caused a worldwide debate on the pricing of patented medicines.
ReplyDeleteA study from Liverpool University showed that sofosbuvir could be produced for as little as $101 for a three-month treatment course.